These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35856379)

  • 1. N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment.
    Micheletto C; Izquierdo JL; Avdeev SN; Rada Escobar RA; Pacheco Gallego MC
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4872-4880. PubMed ID: 35856379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19?
    Di Marco F; Foti G; Corsico AG
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):715-721. PubMed ID: 35113447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine tiherapeutically protects against pulmonary fibrosis in a mouse model of silicosis.
    Huang H; Chen M; Liu F; Wu H; Wang J; Chen J; Liu M; Li X
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31273057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylcysteine alleviates pulmonary alveolar proteinosis induced by indium-tin oxide nanoparticles in male rats: involvement of the NF-κB signaling pathway.
    Liu N; Li G; Guan Y; Wang R; Ma Z; Zhao L; Yao S
    Ecotoxicol Environ Saf; 2022 Aug; 241():113812. PubMed ID: 36068741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats.
    Li S; Yang X; Li W; Li J; Su X; Chen L; Yan G
    Respiration; 2012; 84(6):509-17. PubMed ID: 23006535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined intervention with N-acetylcysteine and desipramine alleviated silicosis development by regulating the Nrf2/HO-1 and ASMase/ceramide signaling pathways.
    Tang M; Yang Z; Liu J; Zhang X; Guan L; Liu X; Zeng M
    Ecotoxicol Environ Saf; 2022 Sep; 242():113914. PubMed ID: 35878501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
    Rushworth GF; Megson IL
    Pharmacol Ther; 2014 Feb; 141(2):150-9. PubMed ID: 24080471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose N-acetylcysteine decreases silica-induced lung fibrosis in the rat.
    Zhang H; Yin G; Jiang H; Zhang C
    J Int Med Res; 2013 Aug; 41(4):1179-86. PubMed ID: 23771710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.
    De Flora S; Balansky R; La Maestra S
    FASEB J; 2020 Oct; 34(10):13185-13193. PubMed ID: 32780893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
    Poe FL; Corn J
    Med Hypotheses; 2020 Oct; 143():109862. PubMed ID: 32504923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals.
    Meyer A; Buhl R; Kampf S; Magnussen H
    Am J Respir Crit Care Med; 1995 Sep; 152(3):1055-60. PubMed ID: 7663783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions.
    Izquierdo-Alonso JL; Pérez-Rial S; Rivera CG; Peces-Barba G
    J Infect Public Health; 2022 Dec; 15(12):1477-1483. PubMed ID: 36410267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress.
    Cui K; Kou JQ; Gu JH; Han R; Wang G; Zhen X; Qin ZH
    BMC Complement Altern Med; 2014 Dec; 14():461. PubMed ID: 25465226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Inflammatory, Antioxidant, and Antifibrotic Effects of Gingival-Derived MSCs on Bleomycin-Induced Pulmonary Fibrosis in Mice.
    Wang X; Zhao S; Lai J; Guan W; Gao Y
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A minireview on N-acetylcysteine: An old drug with new approaches.
    Elbini Dhouib I; Jallouli M; Annabi A; Gharbi N; Elfazaa S; Lasram MM
    Life Sci; 2016 Apr; 151():359-363. PubMed ID: 26946308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression.
    Behr J; Maier K; Degenkolb B; Krombach F; Vogelmeier C
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1897-901. PubMed ID: 9412572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Mechanism of N-acetylcysteine in Treating COVID-19.
    Zhou N; Yang X; Huang A; Chen Z
    Curr Pharm Biotechnol; 2021; 22(12):1584-1590. PubMed ID: 33371832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidant therapy for idiopathic pulmonary fibrosis.
    Hunninghake GW
    N Engl J Med; 2005 Nov; 353(21):2285-7. PubMed ID: 16306527
    [No Abstract]   [Full Text] [Related]  

  • 19. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice.
    Hagiwara SI; Ishii Y; Kitamura S
    Am J Respir Crit Care Med; 2000 Jul; 162(1):225-31. PubMed ID: 10903246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrotic and antioxidant effects of N-acetylcysteine in an experimental cholestatic model.
    Galicia-Moreno M; Favari L; Muriel P
    Eur J Gastroenterol Hepatol; 2012 Feb; 24(2):179-85. PubMed ID: 22241216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.